A proposed charter for clinical trial data monitoring committees: helping them to do their job well
The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
Abstract
Formal monitoring of data from randomised controlled trials (RCTs) is becoming more common. Wide variation exists in the structure and organisation of data monitoring committees (DMCs), with little guidance on how they should operate. We used various strategies to consider the behavioural, procedural, and organisational aspects of data monitoring in RCTs: systematic reviews of DMCs and small group processes in decision making; surveys of reports of RCTs, recently completed and ongoing RCTs, and the policies of major organisations connected with RCTs; detailed case studies of four DMCs that faced difficult decisions; and interviews with experienced DMC members. The findings aided the development of a template for a charter for DMCs. We summarise the findings and outline the key considerations at every stage of the data monitoring process. Widespread use of a charter for the structure and organisation of DMCs would promote a systematic and transparent approach, and enable them to operate more effectively and efficiently.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A randomised trial will often include various committees or groups to facilitate trial coordination and conduct—for example, a trial management group (day-to-day trial conduct) and a trial steering committee (executive decisions).54 55”
From SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials (2025) · cites this paper as [54]
Citations
Cites
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Moher, D., Jones, A., Lepage, L., & for the CONSORT Group (2001) · JAMA · doi:10.1001/jama.285.15.1992 · Cited by 1,027
Value of Flow Diagrams in Reports of Randomized Controlled Trials
Egger, M. (2001) · JAMA · doi:10.1001/jama.285.15.1996 · Cited by 317
Devereaux, P. J., Manns, B. J., Ghali, W. A., Quan, H., & Guyatt, G. H. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00214-3 · Cited by 166
The agonising negative trend in monitoring of clinical trials
DeMets, D. L., Pocock, S. J., & Julian, D. G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03464-9 · Cited by 126
Under-reporting of clinical trials is unethical
Antes, G., & Chalmers, I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12838-3 · Cited by 109
Data Monitoring Committees in Clinical Trials: A Practical Perspective.
Grambsch, P. M. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00271-4 · Cited by 102
Sydes, M. R., Spiegelhalter, D. J., Altman, D. G., Babiker, A. B., Parmar, M. K., & DAMOCLES Group (2004) · Clinical Trials · doi:10.1191/1740774504cn004rr · Cited by 76
Sydes, M. R., Altman, D. G., Babikera, A. B., Parmar, M. K., Spiegelhalter, D. J., & DAMOCLES group (2004) · Clinical Trials · doi:10.1191/1740774504cn003oa · Cited by 49
Research works printed but not linked: 2
- Grant AM, Sydes M, McLeer S, et al. Issues in data monitoring and interim analysis of trials (the DAMOCLES study). Health Technol Assess (in press).
- Anonymous, 2001, Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees (Notices-Draft Guidances)(FR Doc 01-28962), Federal Register, 66, 58151
Cited by
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Adaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829
Bassler, D. (2010) · JAMA · doi:10.1001/jama.2010.310 · Cited by 611
Avery, K. N. L., Williamson, P. R., Gamble, C., O'Connell Francischetto, E., Metcalfe, C., Davidson, P., Williams, H., & Blazeby, J. M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013537 · Cited by 575
Shakur, H., Elbourne, D., Gülmezoglu, M., Alfirevic, Z., Ronsmans, C., Allen, E., & Roberts, I. (2010) · Trials · doi:10.1186/1745-6215-11-40 · Cited by 332
“The DMC composition, name, title and address of the chairman and of each member, will be given in the DMC Charter which will be in line with that proposed by the DAMOCLES Study Group[28].”
Metadata
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 365
- Issue
- 9460
- Pages
- 711-722
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2247856738
- Cited by
- 324
- References
- 15
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 25 · 2023: 17 · 2022: 28 · 2021: 19 · 2020: 21 · 2019: 17 · 2018: 10 · 2017: 24 · 2016: 14 · 2015: 22 · 2014: 13 · 2013: 14 · 2012: 10
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
- Funders
- Medical Research Council
- Health Technology Assessment Programme
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- data monitoring committees, clinical trial monitoring, charters, randomized controlled trials, transparency, operational efficiency
- MeSH terms
- United Kingdom, Clinical Trials Data Monitoring Committees
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A proposed charter for clinical trial data monitoring committees: helping them to do their job well. https://app.cochat.ai/papers/10.1016/s0140-6736(05)17965-3
- The paper
- A proposed charter for clinical trial data monitoring committees: helping them to do their job well. (2005). The Lancet. https://doi.org/10.1016/s0140-6736(05)17965-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.